Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGLBiotechnology
-$1.33 today
- Market cap
- $9.25B
- Beta
- -1.06
- P/E (TTM)
- -46.9
- EPS (TTM)
- -$10.66
Volume 0.64M
Average 0.31M
MDGL Total Liabilities
Everything the company owes to creditors and other parties.
Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 125.7% from a year ago
Total liabilities stood at $720.92M at the end of Q2 FY2026, up 125.7% from a year earlier and up 5.4% from the prior quarter. Over 3 fiscal years it compounded at +58.4% a year.
Context
- Total liabilities amounted to 57.9% of total assets at the end of Q2 FY2026, up 26.5 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +125.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 656.9M USD
- Year-over-year change
- +128.2%
- 4-year CAGR
- +70.8%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 656.9M | +128.2% |
| FY2024 | 2024-12-31 | 287.86M | +22.4% |
| FY2023 | 2023-12-31 | 235.21M | +42.4% |
| FY2022 | 2022-12-31 | 165.18M | +113.9% |
| FY2021 | 2021-12-31 | 77.23M | — |
Total Liabilities vs competitors
How MDGL compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +125.7% is the 3rd highest of 7, against a peer median of +95.4%.
- Total liabilities amounts to 57.9% of total assets for MDGL, versus a peer median of 17.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $720.92M USD | +125.7% | +58.4% | 57.9% | |
| Dec 2025 | €277.91M EUR | +23.2% | +57.9% | 111.7% | |
| Jun 2026 | $113.58M USD | +250.7% | +48.9% | 21.8% | |
| Mar 2026 | $78.01M USD | +91.3% | -4.6% | 18.6% | |
| Jun 2026 | $73.03M USD | +99.5% | +21.0% | 10.4% | |
| Mar 2026 | $51.64M USD | +242.0% | +36.5% | 15.4% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $5.3M USD | -26.2% | -71.5% | 4.9% |
| Peer median (excluding MDGL) | — | +95.4% | +28.8% | 17.0% | |
Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36.27M | 331.55M | 99.92M | 100.02M | 198.69M |
| Short-term Investments | 234.08M | 27.23M | 534.22M | 826.23M | 784.87M |
| Net Receivables | 0 | 0 | 0 | 53.82M | 134.48M |
| Inventory | 0 | 0 | 0 | 34.07M | 74.84M |
| Other Current Assets | 0 | 2.6M | 3.15M | 18.79M | 52.89M |
| Total Current Assets | 271.68M | 361.37M | 637.28M | 1.03B | 1.25B |
| Property, Plant & Equipment (Net) | 1.65M | 1.2M | 3.27M | 4.59M | 6.44M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 4.73M | 7.38M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 1.65M | 1.2M | 3.27M | 9.32M | 13.82M |
| Total Assets | 273.33M | 362.57M | 640.55M | 1.04B | 1.26B |
| Account Payables | 21.38M | 23.83M | 28.04M | 43.6M | 48.88M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.02M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.77M | 14.86M | 17.03M | 34.96M | 260.39M |
| Total Current Liabilities | 76.84M | 115.89M | 118.55M | 169.28M | 310.29M |
| Long-term Debt | 0 | 49.29M | 115.48M | 117.57M | 346.61M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (6.73M) |
| Total Non-current Liabilities | 387K | 49.29M | 116.67M | 118.59M | 346.61M |
| Total Liabilities | 77.23M | 165.18M | 235.21M | 287.86M | 656.9M |
| Common Stock | 2K | 2K | 2K | 2K | 2K |
| Retained Earnings | (667.31M) | (962.66M) | (1.34B) | (1.8B) | (2.09B) |
| Accumulated OCI | (80K) | (32K) | 468K | 468K | 873K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 196.11M | 197.39M | 405.33M | 754.38M | 602.69M |
| Total Debt | 797K | 49.89M | 117.19M | 119.57M | 354.36M |
| Net Debt | (35.47M) | (281.66M) | 17.28M | 19.55M | 155.67M |
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
Intrinsic Alpha fair value
Locked
Current Price
$398.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.